COPD Trial, Recruiting NCT06780046 Sponsor: AstraZeneca Condition: COPD
Back to Copd

COPD Trial, Recruiting

NCT06780046
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 or older (any sex) who have a confirmed diagnosis of COPD based on 2024 GOLD guidelines, which includes a history of exposure to risk factors (such as smoking) and breathing test results showing airflow limitation, along with a symptom score of 10 or higher on a standard COPD questionnaire
  • People whose COPD is classified as GOLD Group E, meaning they have had 2 or more moderate flare-ups, or at least 1 severe flare-up requiring a hospital stay, in the past year
  • People with severe or very severe COPD (GOLD stage 3 or 4), where breathing tests show lung function has dropped below 50% of what is expected

Who may not be able to join:

  • People who have advanced scarring lung disease affecting 50% or more of the lungs
  • People who have high-risk pulmonary hypertension (high blood pressure in the lungs) and are currently on a three-medication treatment plan for it
  • People who have active cancer and are currently receiving systemic treatment (such as chemotherapy or similar therapies that work throughout the whole body)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 1-877-240-9479

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
31 January 2025
Est. completion
30 September 2027

Where this trial is recruiting

🇧🇷 Brazil

Primary endpoints

Incidence of hospitalizations; Incidence of exacerbations; Incidence of Mortality

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov